Citadel Advisors
ANRO icon

Citadel Advisors’s Alto Neuroscience ANRO Stock Holding History

Citadel Advisors’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$699K Buy
31,100
+14,300
+85% +$265K ﹤0.01% 8498
2025
Q4 		$299K Buy
+16,800
New +$212K ﹤0.01% 10163
2025
Q2 		– Sell
-5,100
Closed -$11K – 15469
2025
Q1 		$11K Sell
5,100
-7,800
-60% -$27.9K ﹤0.01% 13516
2024
Q4 		$54.6K Sell
12,900
-27,400
-68% -$171K ﹤0.01% 12301
2024
Q3 		$461K Buy
+40,300
New +$493K ﹤0.01% 8440

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors's ANRO Position: Q1 2026 in Review

Citadel Advisors sold out of Alto Neuroscience (ANRO) in Q1 2026, closing a stake of 12,973 shares — an estimated $240K sold.

Citadel Advisors first reported a position in ANRO in Q1 2024 and held it in 5 quarters. The position peaked at $4.13M in Q4 2024. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Citadel Advisors reported no remaining Alto Neuroscience position as of Q1 2026 after selling out during the quarter.
  • Citadel Advisors sold 12,973 Alto Neuroscience shares in Q1 2026, an estimated $240K.
  • Citadel Advisors first reported a position in Alto Neuroscience in Q1 2024 and held it in 5 quarters.
  • Citadel Advisors's Alto Neuroscience position peaked at $4.13M in Q4 2024.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.